Ichnos Sciences to present at AACR

By The Science Advisory Board staff writers

March 29, 2022 -- Biotechnology company Ichnos Sciences will present preclinical data for ISB 1442, a bispecific antibody, at the American Association for Cancer Research (AACR) annual meeting, held April 8-13, 2022.

ISB 1442 is currently being investigated in blood cancers, including relapsed/refractory multiple myeloma, T cell acute lymphoblastic leukemia, and acute myeloid leukemia. The company said that enrollment in the first-in-human ISB 1442 trial is expected to start in mid-2022.

The poster is titled "ISB 1442, a first-in-class CD38 and CD47 bispecific antibody innate cell modulator for the treatment of CD38+ malignancies" (2903/18).

Copyright © 2022 scienceboard.net

Cell & Gene Meeting on the Mesa
October 11-13
Carlsbad, California United States
IDWeek 2022
October 19-23
District of Columbia United States
American Society of Human Genetics Annual Meeting
October 25-29
Los Angeles, California United States
International Society for Pharmaceutical Engineering Annual Meeting
October 30 - November 2
Orlando, Florida United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter